FDA Clears Magstim TMS Horizon 3.0 with StimGuide Pro Treatment for Patients with Depression, Obsessive Compulsive Disorder, Anxious Depression
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
30 janv. 2024 09h18 HE | Magstim EGI
FDA clears Magstim TMS System Horizon 3.0 with StimGuide Pro providing treatment for patients patients with depressive or obsessive-compulsive conditions
22157.jpg
United Kingdom Mental Health Apps Market Size, Share & Trends Analysis Report 2023-2030 Featuring Mindspace, Calm, Headspace, Youper, MoodMission, and Sanvello Health
24 janv. 2024 10h27 HE | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "U.K. Mental Health Apps Market Size, Share & Trends Analysis Report By Platform (Android, iOS), By Application (Depression & Anxiety...
full_colour.png
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
18 janv. 2024 16h30 HE | GH Research PLC
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
MindFit Toolkit - Mental Wellness for Men by Canadian Men's Health Foundation
Canadian Men’s Health Foundation reports that more men are addressing stress, anxiety and depression
18 janv. 2024 08h00 HE | Canadian Men's Health Foundation
CMHF is helping more men tackle chronic stress, anxiety and depression with the MindFit Toolkit, presented by TELUS Health.
Nexstim Agrees on a
Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression Patients
04 janv. 2024 02h00 HE | Nexstim Oyj
Press release, Helsinki, 4 January 2024 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression...
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
02 janv. 2024 08h00 HE | Healis Therapeutics
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...
Emergen logo.png
Global Deep Brain Stimulation Market Size to Reach USD 4.27 Billion in 2032 | Emergen Research
12 déc. 2023 07h31 HE | Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global Deep Brain Stimulation (DBS) market, valued at USD 1.70 Billion in 2022, is projected to witness a robust revenue Compound Annual Growth Rate...
Helping Children and
Helping Children and Adolescents with Emotional Problems: Free Webinar for Parents and Educators from the Brain & Behavior Research Foundation
16 nov. 2023 13h00 HE | Brain & Behavior Research Foundation
New York, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Children’s mental health is a major concern and improving the potential for early intervention is essential. The Brain & Behavior Research Foundation...
Global Maternal Mental Health Market
Maternal Mental Health Market Size, Share & Trends Analysis Report 2023-2030: Rise In Awareness Programs and Efforts to Improve Practices Around Maternal Mental Healthcare
14 nov. 2023 09h23 HE | Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Maternal Mental Health Market Size, Share & Trends Analysis Report By Disease Indication (Postpartum Depression, Dysthymia), By Therapy...
GH Research Logo_white background.jpg
GH Research Reports Third Quarter Financial Results and Provides Business Updates
09 nov. 2023 16h45 HE | GH Research PLC
DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...